Lisa Miller‐Phillips

470 total citations
8 papers, 215 citations indexed

About

Lisa Miller‐Phillips is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Lisa Miller‐Phillips has authored 8 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Lisa Miller‐Phillips's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Genomics and Diagnostics (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Lisa Miller‐Phillips is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Genomics and Diagnostics (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Lisa Miller‐Phillips collaborates with scholars based in Germany, Austria and United States. Lisa Miller‐Phillips's co-authors include Sebastian Stintzing, Dominik Paul Modest, Volker Heinemann, Tobias Heintges, Markus Moehler, Thomas Kirchner, Ludwig Fischer von Weikersthal, Werner Scheithauer, Frank Kullmann and G. Seipelt and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Lisa Miller‐Phillips

8 papers receiving 214 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Miller‐Phillips Germany 5 189 76 67 56 52 8 215
Helena Taflin Sweden 10 166 0.9× 60 0.8× 49 0.7× 45 0.8× 58 1.1× 25 253
Catherine Leger France 5 216 1.1× 77 1.0× 96 1.4× 28 0.5× 33 0.6× 10 263
Loïck Vidot France 5 224 1.2× 85 1.1× 78 1.2× 27 0.5× 29 0.6× 13 273
Pierre-Guillaume Poureau France 5 219 1.2× 72 0.9× 93 1.4× 27 0.5× 33 0.6× 12 272
Rosa Rita Silva Italy 8 189 1.0× 47 0.6× 86 1.3× 22 0.4× 51 1.0× 18 253
Derek McWhirter United Kingdom 7 170 0.9× 60 0.8× 74 1.1× 50 0.9× 34 0.7× 15 263
Sunyoung S. Lee United States 10 99 0.5× 43 0.6× 58 0.9× 112 2.0× 48 0.9× 43 265
Riham Katkhuda United States 6 150 0.8× 68 0.9× 65 1.0× 16 0.3× 41 0.8× 15 197
Maria Bensi Italy 8 180 1.0× 81 1.1× 58 0.9× 14 0.3× 58 1.1× 33 245
Aibing Xu China 7 74 0.4× 40 0.5× 37 0.6× 82 1.5× 39 0.8× 10 179

Countries citing papers authored by Lisa Miller‐Phillips

Since Specialization
Citations

This map shows the geographic impact of Lisa Miller‐Phillips's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Miller‐Phillips with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Miller‐Phillips more than expected).

Fields of papers citing papers by Lisa Miller‐Phillips

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Miller‐Phillips. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Miller‐Phillips. The network helps show where Lisa Miller‐Phillips may publish in the future.

Co-authorship network of co-authors of Lisa Miller‐Phillips

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Miller‐Phillips. A scholar is included among the top collaborators of Lisa Miller‐Phillips based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Miller‐Phillips. Lisa Miller‐Phillips is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Miller‐Phillips, Lisa & Eric A. Collisson. (2023). RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming. Current Treatment Options in Oncology. 24(8). 1088–1101. 4 indexed citations
2.
Stahler, Arndt, Volker Heinemann, Ingrid Ricard, et al.. (2020). Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. Journal of Cancer Research and Clinical Oncology. 146(8). 2077–2087. 9 indexed citations
3.
Heinemann, Volker, Ludwig Fischer von Weikersthal, Thomas Decker, et al.. (2020). FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. British Journal of Cancer. 124(3). 587–594. 94 indexed citations
4.
Heinrich, Kathrin, Lisa Miller‐Phillips, Amanda Tufman, et al.. (2020). AIO-MentorUs – gelebte Nachwuchsförderung in der AIO. Forum. 35(1). 9–12. 2 indexed citations
5.
Miller‐Phillips, Lisa, Volker Heinemann, Arndt Stahler, et al.. (2019). Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA-21’s influence on gene expression in the EGFR signaling pathway.. Journal of Clinical Oncology. 37(15_suppl). 3593–3593. 5 indexed citations
6.
Stintzing, Sebastian, Lisa Miller‐Phillips, Ludwig Fischer von Weikersthal, et al.. (2018). Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.. Journal of Clinical Oncology. 36(15_suppl). 3508–3508. 1 indexed citations
7.
Miller‐Phillips, Lisa, Ludwig Fischer von Weikersthal, Florian Kaiser, et al.. (2018). Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306). Annals of Oncology. 29. viii39–viii39. 2 indexed citations
8.
Stintzing, Sebastian, Lisa Miller‐Phillips, Dominik Paul Modest, et al.. (2017). Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. European Journal of Cancer. 79. 50–60. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helena Taflin Breakdown of academic impact, for papers by Catherine Leger Breakdown of academic impact, for papers by Loïck Vidot Breakdown of academic impact, for papers by Pierre-Guillaume Poureau Breakdown of academic impact, for papers by Rosa Rita Silva Breakdown of academic impact, for papers by Derek McWhirter Breakdown of academic impact, for papers by Sunyoung S. Lee Breakdown of academic impact, for papers by Riham Katkhuda Breakdown of academic impact, for papers by Maria Bensi Breakdown of academic impact, for papers by Aibing Xu
Rankless by CCL
2026